抗击动脉样硬化与奇拉性/相位双工程纳米酶,具有微环境编程的解和形作用
Chengjin Ding1, Jiao Min1, Yongkang Tan1
1Key Laboratory of Cardiovascular and Cerebrovascular Medicine, Department of Pharmaceutics, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, P. R. China.
这项研究开发了一种新的纳米酶来对抗细胞衰老,显示其在老化模型中的有效性. D-handed PtPd2CuFe纳米酶表现出老化和老化特性,为治疗诸如动脉样硬化等与年龄相关的疾病提供了潜力.
科学领域:
- 生物材料科学 生物材料科学
- 衰老研究研究 衰老研究
- 纳米技术纳米技术
背景情况:
- 细胞衰老是衰老和疾病发展的关键因素.
- 现有的抗衰老疗法有其局限性.
- 需要新的方法来有效地准衰老.
研究的目的:
- 开发和描述一种基于高合金 (HEA) 的纳米酶,用于对抗细胞衰老.
- 研究纳米酶的催化活性和抗衰老治疗功能.
- 探索纳米酶老化作用的潜在机制及其在治疗与年龄相关疾病的潜力.
主要方法:
- 基于HEA的无形纳米酶的制造和表征.
- 在正常和老化条件下评估纳米酶催化活性 (过氧化和超氧化脱酶).
- 在老化模型中使用D-handed PtPd2CuFe验证依赖于奇拉的老化性能.
- 多种Omics分析以阐明作用机制.
- 对度依赖的抗衰老作用和老化潜力的评估.
主要成果:
- 该纳米酶对其抗衰老功能表现出关键的过氧化物和超氧化物脱酶 (SOD) 活性.
- D-handed PtPd2CuFe在各种老化模型中表现出显著的老化性能.
- 多Omics数据揭示了纳米酶诱导的铁醇集群的破坏,以及诱导衰老细胞中的cuproptosis和ferroptosis.
- 该纳米酶表现出度依赖的抗衰老效应,即使在超低剂量下也表现为老态.
- D-handed PtPd2CuFe纳米酶在治疗动脉样硬化 - - 一种涉及衰老细胞的疾病 - - 中被证明是有效的.
结论:
- 开发的基于HEA的纳米酶,特别是D-handed PtPd2CuFe,是抗细胞衰老的有前途的治疗剂.
- 该纳米酶的机制涉及恢复线粒体功能和预防ferroptosis/cuproptosis.
- 它的双重老化和老化特性为与年龄相关的疾病,包括动脉样硬化,提供了多功能治疗潜力.
更多相关视频
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
相关概念视频
Chirality in Nature
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
